The results from this study found that patients with melanoma with no previous history of being treated with temozolomide were able to tolerate temozolomide plus sorafenib.
Journal: Clinical Cancer Research (December 2009)
Authors: Amaravadi RK, Schuchter LM, McDermott DF, et al.
Purpose: To assess the combination of the oral alkylating agent temozolomide and the oral multikinase inhibitor sorafenib in patients with advanced melanoma.
Results: Temozolomide plus sorafenib was found to be well tolerated and showed activity in patients with melanoma who had no previous history of temozolomide treatment. The authors conclude that the temozolomide and sorafenib combination warrants further investigation in patients with advanced melanoma.